MedTrace Logo

Escitalopram in Adult Patients With Major Depressive Disorder

NCT00668525 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 877

Last updated 2010-05-11

Study results available
· View outcomes & findings →

Summary

This is a short-term study to evaluate the efficacy, safety, and tolerability of escitalopram in adult patients (18 to 65 years of age) with moderate to severe depression. Patients completing the study may be eligible to enter a long-term open-label extension study with escitalopram.

Conditions

Interventions

DRUG

Escitalopram

Escitalopram low dose, oral administration, once daily dosing for 8 weeks.

DRUG

Placebo

Placebo, oral administration, once daily dosing for 8 weeks

DRUG

Escitalopram

Escitalopram high dose, oral administration, once daily dosing for 8 weeks

Sponsors & Collaborators

  • Forest Laboratories

    lead INDUSTRY

Principal Investigators

  • Carl Gommoll, MS · Forest Laboratories

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2009-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00668525 on ClinicalTrials.gov